The estimated Net Worth of Steven R. Ph.D. Gullans is at least $93.8 Tausend dollars as of 19 May 2014. Steven Gullans owns over 25,000 units of NeuroBo Pharmaceuticals Inc stock worth over $93,750 and over the last 12 years Steven sold NRBO stock worth over $0.
Sign up
Steven Gullans NRBO stock SEC Form 4 insiders trading
Steven has made over 2 trades of the NeuroBo Pharmaceuticals Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Steven bought 25,000 units of NRBO stock worth $231,000 on 19 May 2014.
The largest trade Steven's ever made was buying 496,121 units of NeuroBo Pharmaceuticals Inc stock on 25 March 2013 worth over $3,472,847. On average, Steven trades about 130,280 units every 105 days since 2013. As of 19 May 2014 Steven still owns at least 25,000 units of NeuroBo Pharmaceuticals Inc stock.
You can see the complete history of Steven Gullans stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Steven Gullans's mailing address?
Steven's mailing address filed with the SEC is C/O NEUROBO PHARMACEUTICALS, INC., 177 HUNTINGTON AVENUE, SUITE 1700, BOSTON, MA, 02115.
Insiders trading at NeuroBo Pharmaceuticals Inc
Over the last 5 years, insiders at NeuroBo Pharmaceuticals Inc have traded over $0 worth of NeuroBo Pharmaceuticals Inc stock and bought 2,544,530 units worth $7,964,379 . The most active insiders traders include St Co., Ltd Dong A, Tae Heum Jeong und Steven R. Ph.D. Gullans. On average, NeuroBo Pharmaceuticals Inc executives and independent directors trade stock every 0 days with the average trade being worth of $9,541,988. The most recent stock trade was executed by St Co., Ltd Dong A on 23 June 2024, trading 2,544,530 units of NRBO stock currently worth $7,964,379.
What does NeuroBo Pharmaceuticals Inc do?
neurobo pharmaceuticals, inc., a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. its therapeutics programs include nb-01 for the treatment of painful diabetic neuropathy; nb-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. neurobo pharmaceuticals, inc. was incorporated in 2017 and is headquartered in boston, massachusetts.
What does NeuroBo Pharmaceuticals Inc's logo look like?
Complete history of Steven Gullans stock trades at Tetraphase Pharmaceuticals und NeuroBo Pharmaceuticals Inc
NeuroBo Pharmaceuticals Inc executives and stock owners
NeuroBo Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Dr. Ben Gil Price M.D.,
CEO & Pres -
Nicola Shannon,
Vice President - Clinical Operations -
Akash Bakshi,
Sr. VP & COO -
Michael Miller,
Investor Relations -
Douglas Swirsky,
Independent Director -
Michael Salsbury,
Independent Director -
Jeong Gyun Oh,
Independent Director -
Tae Heum Jeong,
Independent Director -
Jason Groves,
Independent Director -
Mark Versavel,
Chief Medical Officer -
jeong Gu Kang,
President, Chief Executive Officer, Interim Chief Financial Officer, Secretary, Treasurer and Director -
Na Yeon Kim,
Independent Chairman of the Board -
Frank Kondrad,
VP of Corp. & Bus. Devel. -
Dr. Matthew Bardin BCPS, Pharm.D.,
Sr. VP of Operations -
Dr. Nadja Mannowetz Ph.D.,
Sr. VP -
Dr. Andrew Bartynski Ph.D.,
Sr. VP -
Dr. Gil Price M.D.,
CEO, Pres & Chief Medical Officer -
Dr. Jeong Gu Kang Ph.D.,
Pres, CEO, Sec., Interim CFO, Treasurer & Director -
St Co., Ltd Dong A,
-
Mark A Glickman,
Director -
Akash Bakshi,
SVP and COO -
Steven R. Ph.D. Gullans,
Director -
James Patrick Tursi,
Director -
Ben Gil Price,
CEO and President -
D Gordon Strickland,
Director -
Richard Kang,
Director -
Inc.E&Healthcare Investment...,
-
Hyung Heon Kim,
CEO & President -
Marshall H Woodworth,
Chief Financial Officer